A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Alisertib (Primary) ; Bortezomib (Primary) ; Rituximab
- Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 16 Feb 2018 Planned primary completion date changed from 30 Dec 2017 to 31 Mar 2019.
- 16 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Dec 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017.